US Bancorp DE and several other financial institutions, including
Citigroup and
JPMorgan Chase & Co. expanded their shares in
Novartis AG. The Swiss multinational pharmaceutical corporation announced plans to open another
Radioligand Therapy Manufacturing Site in
Denton, Texas, boosting their US-based operations. Additionally, its shares reached a record peak of 167.87 USD. A significant event was the completion of
Novartis' acquisition of
Avidity Biosciences, leading to the strengthening of their late-stage neuroscience pipeline and development of xRNA strategy. Novartis also left the Indian market in a deal worth $159 million, causing a sharp surge in Mumbai-listed shares. However, the company's generics dented its blockbuster heart drug, leading to a drop in share value. There have also been discussions about Novartis's valuation, based on mixed fair value signals, positive phase III data, and upcoming regulatory milestones. The direction of
Novartis' shares is also under scrutiny, amid speculation about growth opportunities following a year-to-date rally.
Novartis Stocks News Analytics from Wed, 25 Jun 2025 05:06:04 GMT to Sat, 28 Feb 2026 13:44:59 GMT -
Rating 8
- Innovation 5
- Information 8
- Rumor -2
